Search Results - "TAIT, N. S"

Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics by CONLEY, B. A, EGORIN, M. J, SRIDHARA, R, FINLEY, R, HEMADY, R, WU, S, TAIT, N. S, VAN ECHO, D. A

“…A phase I trial of all-trans-retinoic acid (ATRA) was conducted to establish the maximum tolerable dose (MTD) of ATRA given once daily to patients with solid…”
Get full text

Myocardial toxic effects during recombinant interleukin-2 therapy by Nora, R, Abrams, J S, Tait, N S, Hiponia, D J, Silverman, H J

“…Arterial and pulmonary artery catheters were used to monitor the cardiopulmonary effects of recombinant interleukin-2 (rIL-2) given iv at a dose of 100,000…”
Get more information

Pharmacokinetic and Pharmacodynamic Study of the Combination of Docetaxel and Topotecan in Patients With Solid Tumors by ZAMBONI, William C, EGORIN, Merrill J, TKACZUK, Katherine H, VAN ECHO, David A, DAY, Roger S, MEISENBERG, Barry R, BROOKS, Sandra E, DOYLE, L. Austin, NEMIEBOKA, Noble N, DOBSON, Jason M, TAIT, Nancy S

“…The sequence in which chemotherapeutic agents are administered can alter their pharmacokinetics, therapeutic effect, and toxicity. We evaluated the…”
Get full text

Phase I study of docetaxel and topotecan in patients with solid tumors by TKACZUK, Katherine H, ZAMBONI, William C, TAIT, Nancy S, MEISENBERG, Barry R, DOYLE, L. Austin, EDELMAN, Martin J, HAUSNER, Petr F, EGORIN, Merrill J, VAN ECHO, David A

“…Both docetaxel (DOC), a promoter and stabilizer of microtubule assembly, and topotecan (TOPO), a topoisomerase I inhibitor, have shown antitumor activity in a…”
Get full text

Drug Response Indicator Test (DRIT) as a predictive test for treatment outcomes in advanced breast cancer patients (ABC) by Tkaczuk, K. H., Tait, N. S., Ioffe, O., Tan, M., Mohiuddin, M., Chumsri, S., VanEcho, D. A., Sutula, M. J., Lesko, S., Deamond, S., Ts'o, P.

“…Abstract only 1119 Background: There are limited options for selecting an optimal treatment regimen for ABC patients (pts). DRIT is a platform technology that…”
Get full text

Serial monitoring for circulating cancer cells in blood samples of stage 1–4 breast cancer patients by Tkaczuk, K. H., Tait, N. S., Chua, K., Feldman, F., Lesko, S. A., Lun, Z., Tan, M., Ts’o, P. O.

“…Abstract only 623 Serial monitoring for presence, number & characterization of circulating cancer cells (CCC) may provide valuable information that may be…”
Get full text

PC-cell derived growth factor (PCDGF/GP88): A novel circulating biomarker in breast cancer (BC) patients by Serrero, G., Tkaczuk, K. H., Jones, L., Goloubeva, O., Tait, N. S., Feldman, F. S., Dai, H.

“…Abstract only…”
Get full text

P1-12-20: The Safety and Tolerability of Vorinostat in Combination with Lapatinib in Advanced Solid Tumors by Chumsri, S, Tait, NS, Medeiros, MM, Bauer, KS, Betts, K-MT, Lewis, JC, Bao, T, Feigenberg, SJ, Kesmodel, SB, Stearns, V, Edelman, MJ, Sausville, EA, Tkaczuk, KHR

“…Abstract Background: Lapatinib has been previously shown to markedly decrease cancer stem cells (CSC) in HER2−positive breast cancer. In preclinical models, we…”
Get full text

A retrospective study of drug response indicator test (DRIT) as a predictive test for therapeutic treatment outcomes of advanced breast cancer patients (ABC) by Tkaczuk, KR, Tait, NS, Ioffe, O, Rogers, W, Tan, M, Lesko, SA, Lum, ZP, Deamond, SF, Shan, E, Daniel, JR, VanEcho, DA, Ts'o, PO

“…Abstract Abstract #6075 We conducted a retrospective study of DRIT, an investigational diagnostic test to predict chemotherapy and endocrine therapy treatment…”
Get full text

Total Hadronic Photoabsorption Cross Sections of Nuclei for Photons in the GeV Energy Range by Brookes, G. R., Clough, A. S., Freeland, J. H., Galbraith, W., King, A. F., Armstrong, T. A., Hogg, W. R., Lewis, G. M., Robertson, A. W., Rawlinson, W. R., Tait, N. R. S., Thompson, J. C., Tolfree, D. W. L.

Get full text

The photoproduction of eta-mesons between 950 MeV and 2.2 GeV by Booth, P. S. L., Butler, M. F., Carroll, L. J., Holt, J. R., Jackson, J. N., Range, W. H., Williams, E. G. H., Wormald, J. R., Tait, N. R. S.

Get full text

Total Hadronic Cross Section of γ Rays in Hydrogen in the Energy Range 0.265-4.215 GeV by Armstrong, T. A., Hogg, W. R., Lewis, G. M., Robertson, A. W., Brookes, G. R., Clough, A. S., Freeland, J. H., Galbraith, W., King, A. F., Rawlinson, W. R., Tait, N. R. S., Thompson, J. C., Tolfree, D. W. L.

Get full text

A National Nuclear Structure Facility for Britain by Tait, N. R. S., Voss, R. G. P.

“…A large electrostatic tandem accelerator has been designed to provide a nuclear structure facility in Britain. The machine is intended to operate initially at…”
Get full text

Ion Exchange Processes in a Clean Vacuum Electrostatic Accelerator Tube by Aitken, T. W., Eastham, D. A., Joy, T., Tait, N. R. S., Thorn, R.

Get full text

Differential cross-section measurements for π0 photoproduction in the region of the third nucleon resonance by Booth, P. S. L., Butler, M. F., Carrol, L. J., Holt, J. R., Jackson, J. N., Range, W. H., Williams, E. G. H., Wormald, J. R., Tait, N. R. S.

Get full text